Cytokine production by human leukocytes with different expressions of natural antiviral immunity and the effect of antibodies against interferons and TNF-± by Orzechowska, Beata et al.
Arch. Immunol. Ther. Exp., 2007, 55, 111–117 DOI  10.1007/s00005-007-0013-y
PL ISSN 0004-069X
Cytokine production by human leukocytes 
with different expressions of natural antiviral immunity
and the effect of antibodies against interferons 
and TNF-α α
Beata Orzechowska, Zenon Antoszków, Iwona Siemieniec, Maria Lorenc, 
Bogna Jatczak and Zofia Błach−Olszewska
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroc³aw, Poland
Received: 2006.09.08, Accepted: 2006.11.27, Published online first: 2007.03.20
Abstract
Introduction: Two activities of innate antiviral immunity were studied: the resistance of human peripheral blood mononuclear
cells (PMBCs) ex vivo to viral infection and the production of cytokines.
Materials and Methods: Samples of blood were taken from healthy blood donors and from persons with frequent infections
of the upper respiratory system. PMBCs were isolated by gradient centrifugation. Vesicular stomatitis virus (VSV) was used
as the indicatory virus to infect PMBCs. The cytokines: IFN, TNF, and IL-6 were titrated by biological methods and IL-10
by ELISA.
Results: Blood donors were divided for two groups: those with VSV-resistant and those with VSV-sensitive PMBCs and
secretion of cytokines by them was compared. The resistant PMBCs produced more cytokines than the sensitive ones. A sta-
tistically significant difference, was found only in the case of the IFNs. To examine the contribution of IFNs and TNF in
maintaining resistance, leukocytes from both groups were treated with specific anti-cytokine antibodies. The authors’ previ-
ous study showed that the elimination of spontaneous IFN-α, IFN-β, IFN-γ, and TNF-α from resistant leukocytes resulted
in increased VSV replication This indicates the important role of cytokines. In VSV-sensitive PMBCs, anti-IFN-α showed
the opposite effect (decreased virus replication). In the absence of spontaneous IFN-α, disturbances in cytokine production
were observed.
Conclusions: Complete resistance of PMBC to VSV infection is accompanied by higher cytokine release, The paradoxical
effect of anti-IFN-α on virus replication in leukocytes sensitive to viral infection may be attributed to changes in the cytokine
profile balance, i.e. high TNF production by VSV-infected leukocytes and a complete reduction of IL-6 production. 
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INTRODUCTION
Immune responses in vertebrates, invertebrates, and
plants are initiated by the recognition of a large number
of pathogens by cells of the innate immune system [2,
14]. In vertebrates, systemic reactions develop when the
innate immune system is effectively activated.
Phagocytosis with intracellular killing and the produc-
tion and activity of cytokines such as interferons (IFNs),
members of the tumor necrosis factor (TNF) superfam-
ily, interleukins (IL-12, IL-18), chemokines, and adhe-
sion molecules are very important. Another activity of
the innate immune system is MHC-independent killing
of infected cells by natural killer cells and by comple-
ment activated along the alternative or lectin pathways
[6, 8, 22, 27]. The resistance of cells, especially leuko-
cytes ex vivo, to viral infections is also considered to be
one of the reactions of innate immunity [2] which pro-
tect the host against invasion by microorganisms. As
observed in many laboratories, high levels of cytokines
with antiviral activity (IFNs and TNF) are frequently
considered to be indicators of innate antiviral immunity.
Our own results, obtained several years ago, showed dif-
ferent degrees of resistance to viral infection in organcultures of human placenta, amniotic membrane, and
umbilical cord vein [18, 29]. Resistance was directed
against viruses belonging to different taxonomic groups:
vesicular stomatitis virus (VSV, Rhabdoviridae),
encephalomyocarditis virus (EMCV, Picornaviridae), and
herpesvirus type 1 (Herpesviridae). Furthermore, resis-
tance to different viral infections was found in cultures of
murine and human leukocytes [16, 28]. Therefore resis-
tance is non-specific. It can be reduced by specific anti-
bodies against IFN-α, IFN-β, IFN-γ, and TNF-α, which
indicates a role of endogenous cytokines. Resistance is
highest immediately after organ culture and leukocyte
isolation and is reduced after 1–5 days of in vitro incuba-
tion before infection with virus. The non-specific charac-
ter of antiviral immunity, its dependence on endogenous
IFNs and TNF, and the fact that it is present in cells ex
vivo suggest that it could be considered innate immunity.
Using infection of peripheral blood leukocytes with
VSV, we developed a new method for detecting innate
immunity [16]. VSV was selected as an indicatory virus
because it does not cause natural infections in the
European human population, so specific antibodies
against VSV are absent in human sera, which excludes
the participation of acquired immunity in this experi-
mental model of innate immunity. The virus also infects
a wide spectrum of human and animal cells, including
different types of immune cells. In our study, the whole
peripheral blood mononuclear cell (PBMC) population
was used, which mimics an in vivo natural system.
Separated cell fractions are then needed for further
studies. The results of preliminary experiments indicate
that the innate immunity expressed by PMBCs is lower
than that of the separate cell populations. These results
suggest the presence of some regulatory mechanisms in
PMBCs.
We used VSV replication in PBMCs to identify three
different levels of natural immunity. A VSV replication
titer higher than 4 log TCID50 was considered a deficien-
cy of innate immunity, a titer of 2–3 log indicated partial
resistance, and a titer of 0–1 log indicated complete
innate antiviral immunity. Using this method, we have
studied the innate immunity of more than 300 people.
Innate immunity was different among individuals.
A lower level was often observed in persons with frequent
infections of the upper respiratory track [16] and in those
with frequent activation of herpes labialis. Deficiency of
innate immunity is associated with the absence of remis-
sion and short survival time of patients with acute
leukemia [4]. In contrast, all patients with complete
immunity achieved long-lasting complete remission after
chemotherapy and were still alive after finishing the
study. An age dependence for immunity was also shown
by Rybka et al. [21]. Leukocytes from the peripheral
blood of healthy donors (30–40 years old) were mostly
resistant to viral infection. In contrast, leukocytes isolated
from cord blood vein and from elderly individuals (>60)
were vulnerable to viral infection. When innate immuni-
ty is over-stimulated, the reactions may lead to significant
wastage in the body. Over-stimulation accompanies and
participates in the development of autoimmunity or neu-
rodegenerative diseases [1, 12, 19, 20, 23, 24]. Therefore,
innate reactions must be under rigorous control [3].
We decided to compare two evaluation methods of
innate immunity: a direct method based on PMBC resis-
tance to VSV infection and an indirect method based on
cytokine secretion. The production of IFNs and of TNF-α,
IL-6, and IL-10 was studied. The role of every cytokine in
innate immunity is different. The IFNs and TNF-α are
the most important cytokines in antiviral immunity, IL-6,
according to Jones [10], directs the transition from innate
to acquired immunity, and IL-10 regulates immunity [15].
MATERIALS AND METHODS
Blood donors samples
Peripheral venous blood samples (10 ml) were taken
from a group of healthy volunteers (12 persons) and from
currently healthy persons with recurrent infections of the
upper respiratory tract (9 persons). The latter group was
sent to a laboratory of virology to find the reason for their
low immunity. The persons were 18–72 years old. 
The study was performed with permission of the
local ethics committee.
Cell cultures
PMBCs were isolated from heparinized peripheral
blood by gradient centrifugation in Dextran-Uropolin
(Gradisol G) with a density of 1.115 g/ml (Aqua Medica,
Poznañ, Poland). Five ml of blood were layered on 3 ml
of Gradisol and centrifuged for 25 min at 400 g.
Leukocytes from the border of the two phases were col-
lected, washed two times with RPMI supplemented with
2% calf serum (CS), and suspended in the medium at
a concentration of 2×106 cells/ml. The cell suspension
was cultured at 37°C (in 5% CO2 in air).
L929 cells (ATCC CCL 1)
The murine fibroblast-like cell line was maintained in
Eagle medium with 10% CS, antibiotics (100 U/ml penicil-
lin and 100 µg/ml streptomycin), and 2 mM L-glutamine.
A549 cells (ATCC CCL 185)
The human epithelial-like cell line was maintained
in Dulbecco medium supplemented with 10% CS,
antibiotics, and L-glutamine.
Viruses
VSV, Indiana strain, Rhabdoviridae, Vesiculovirus,
was multiplied and titrated in L929 cells. EMCV,
Columbia MM strain, Picornaviridae, Cardiovirus, was
multiplied and titrated in L929 cells and used for IFN
titration.
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Resistance/innate immunity was estimated by infec-
tion of leukocytes (2×106 cells/ml) with VSV. They were
infected with a dose of 100 TCID50 (tissue culture infec-
tious dose, based on the cytopathic effect caused by the
virus in about 50% of infected L929 cells) of VSV/ml of
the leukocytes suspensions. After 40 min of adsorption,
the virus was washed out three times with 5 ml EMEM
and the cells were suspended in 1 ml RPMI with 2% CS.
A sample of infected cells was kept at a temperature of
4°C and served as a control of the starting level of the
virus. The other cells were incubated at 37°C and sam-
ples of medium above the infected cells were collected
each day and titrated in L929. The titer of virus is
expressed in TCID50. Based on the replication of VSV
in PBMCs, we identified three different levels of natur-
al antiviral immunity: a VSV replication titer higher
than 4 log TCID50 was considered as deficiency of resis-
tance/innate immunity, a titer of 2–3 log indicated par-
tial resistance, and a titer of 0–1 log indicated complete
resistance/innate antiviral immunity.
Cytokine assay
IFN, TNF, and IL-6 were titrated using biological
methods and IL-10 with ELISA.
IFN was titrated using the biological method of inhi-
bition of the cytopathic effect caused by EMCV virus on
the human cell line A549. In each experiment, calibration
against an internal laboratory standard of human IFN-α/β
was performed and the obtained results were corrected
according to it. The internal standard was calibrated
against the international standard of human leukocyte
IFN 69/19.
TNF was assayed according to Flick and Gifford[7].
The cytotoxic activity of TNF-α in the samples was mea-
sured in L929 cells in the presence of actinomycin
D (Serva, Germany) at a concentration of 2 µg/ml
EMEM. Recombinant human TNF-α (Genetech, USA)
was used as the standard in all assays. In our assay, 1 unit
was equal to 2.5–10 pg/ml of TNF-α.
Production of IL-6 was determined using the IL-6-
-dependent hybridoma cell line 7TD1 38 as previously
described by Van Snick et al. [25]. Briefly, the cells were
cultured in 96-well plates (Costar, MA, USA) at a con-
centration of 2×103 cells/well in the presence of serial
dilutions of the supernatants from uninfected and VSV-
-infected leukocyte cultures. After 72 h the surviving
cells were evaluated colorimetrically by staining the cells
with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoli-
um bromide (MTT, Sigma Chemicals Co., USA) and
lysis of the cells with a sodium dodecyl sulfate (SDS)/
solution in a 45% aqueous solution (v/v) DMF (N, 
N-dimethylformamide, Sigma Chemicals Co., USA).
One unit of IL-6 activity was calculated as the inverse
dilution of a supernatant sample in which a half-maxi-
mal proliferation of 7TD1 cells was registered. In our
assay, one unit correspond to 0.1 ng of recombinant (E.
coli) human IL-6 (R&D Systems, USA). The sensitivity
of the bioassay was 5 U/ml.
IL-10 was quantified using ELISA according to the
producer’s instructions (BD Bioscientes Pharmingen,
USA).
Antibodies against human cytokines
Anti-IFN-α (polyclonal, sheep), anti-IFN-γ (poly-
clonal, goat), and anti-TNF-α (polyclonal, rabbit) anti-
bodies were from Sigma-Aldrich (St. Louis, MO, USA)
and anti-IFN-β (polyclonal, sheep) from the National
Institutes of Health (Bethesda, MD, USA).
Statistical analysis
The data were presented as means, standard devia-
tions (SD), medians, quartiles (25–75%), and ranges
(min.-max.). The significance of differences between
groups was determined using the Student’s t-test and the
Mann-Whitney U-test. Differences between pairs of
measurements in the same patients were tested
using Wilcoxon’s matched-pairs signed-ranks test.
Spearman’s rank correlation test was used for determin-
ing the relationship between the levels of IL-6 and the
concentration of anti-IFN. The analysis was done using
the computer program Statistica Version 5.1, Stat-Soft
(USA), taking p<0.05 as statistically significant.
RESULTS
Human leukocytes present different levels 
of antiviral immunity (cytokine production 
and resistance to viral infection)
In our study we used leukocytes isolated from the
peripheral blood of 21 currently healthy persons with
different innate immunity. The cultures of leukocytes
were infected with VSV (100 TCID50/ml) immediately
after preparation (T=0) and the kinetics of virus repli-
cation was studied during three days of infection. The
results obtained are presented in Fig. 1. The kinetics of
VSV replication was different, so two groups of individ-
uals were distinguished. The first consisted of 7 persons
with resistant to viral infection leukocytes. They had
very low or no viral replication (0–1 log TCID50). The
second group consisted of 14 persons (9 from the group
with frequent infections and 6 healthy blood donors)
with partial immunity or no resistance. VSV replicated
to a titer of 2–5 log. 
In the next experiments, spontaneous and VSV-in-
duced cytokine production in both groups (resistant and
sensitive PMBCs) were measured. We found that VSV
infection only stimulated IFN production, did not sig-
nificantly influence TNF, and reduced IL-6 and IL-10
levels. 
To determine the correlation between the level of
resistance/innate immunity measured by VSV replica-
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levels of IL-6, IL-10, TNF, and IFNs in the supernatants
of two different leukocyte cultures, uninfected and after
infection with VSV. Leukocytes with stronger resis-
tance/innate immunity produced more cytokines; how-
ever, statistical significance was found only in the case of
VSV-induced IFN. Figure 2 presents a comparison of
spontaneous cytokine production by leukocytes with
high and low levels of resistance/innate antiviral 
immunity.
Elimination of IFN-α caused an unexpected reduction 
in VSV replication in sensitive leukocytes 
and a disturbance in cytokine production
In the next experiment the influence of specific anti-
-IFNs and anti-TNF-α antibodies on VSV replication
and the production of cytokines by leukocytes with dif-
ferent antiviral immunity was examined. Before their
application, the antibodies were carefully titrated for
effective neutralization. The amounts were sufficient to
neutralize cytokines produced by leukocytes. The anti-
bodies were added to the leukocytes after VSV adsorp-
tion. The antibodies stimulated viral replication in the
virus-resistant cells (results not shown). This effect indi-
cates that endogenous IFNs and TNF-α participate in
the maintenance of resistance/innate immunity. The
influence of the antibodies on viral replication in leuko-
cytes sensitive to VSV infection is presented in Fig. 3.
Instead of the expected stimulation of virus replication
after endogenous IFN-α elimination, a reduction in
virus titer was observed. We attempted to explain these
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Fig. 1. Kinetics of VSV replication in human PMBCs (n=21).
Leukocytes were infected with VSV immediately after their isola-
tion, washed several times with culture medium, and incubated at
37oC for 3 days. The kinetics of virus replication was studied in
samples collected each day after infection. The samples were
titrated in L929 cells.
Fig. 2. Comparison of spontaneous production of cytokines by VSV-resistant (n=7) and VSV-sensitive (n=14) PMBCs. The samples were
collected after 24 h of cell incubation from uninfected and VSV-infected PMBCs. In the figure, however, spontaneously released cytokines
are presented. Only the IFN level is presented in both the uninfected and VSV-infected PMBCs. To inactivate the virus, the samples of
VSV-infected cells were UV irradiated (on ice) before titration. IFN, TNF, and IL-6 were titrated by biologic methods and IL-10 by ELISA.
Statistics were performed using the Student’s t-test. *Statistically significant.
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123123unexpected results by studying changes in cytokine pro-
files in the absence of endogenous IFNs and TNF-α. It
was found that in the absence of endogenous IFN-α the
profile of cytokine production was changed. The pres-
ence of anti-IFN-α antibodies abolished IL-6 produc-
tion. The lack of IL-6 production was observed in both
resistant and sensitive leukocytes, infected as well as
uninfected. The results of IL-6 production by uninfect-
ed untreated leukocytes and those treated with anti-
-IFNs and anti-TNF-α antibodies are presented in Fig.
4. The other important observation was that in the pres-
ence of anti-IFN-α antibodies, an increased level of
TNF-α, remarkably so in infected leukocytes from the
VSV-sensitive group, was observed (Fig. 5). To confirm
the possible role of TNF in antiviral activity, VSV-
-infected leukocytes sensitive to the virus were treated
with 100 U of TNF-α (the median TNF level in leuko-
cytes treated with antibody against IFN-α). The results
of four independent experiments, presented in Fig. 6,
show a reduction in VSV titer by 2–4 log.
The antibodies against IFN-α also stimulated IL-10
production depending on the level of innate immunity
level (Fig. 7). The addition of antibodies against TNF-α
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Fig. 3. Effect of anti-IFNs and anti-TNF-α antibodies on VSV
replication in PMBCs sensitive to VSV infection. The antibodies
(a=anti) were applied to VSV-infected PMBCs after virus adsorp-
tion. The kinetics of viral replication in antibody-treated cells was
compared with untreated cells. Samples of media were collected
over three days. VSV was titrated in each sample in L929 cells.
Results from the first day after VSV infection are presented.
Statistics were performed using the Mann-Whitney test.
*Statistically significant.
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Fig. 4. Effect of antibodies against IFNs and TNF on IL-6 produc-
tion by PBLs. Anti-cytokines antibodies (a=anti) were added
immediately after virus adsorption. The level of IL-6 was deter-
mined in sensitive and resistant PMBCs. Statistics were performed
with the non-parametric Wilcoxon test. *,**Statistically significant. 
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Fig. 5. Effect of anti-IFNs antibodies on TNF production in sensi-
tive leukocytes infected with VSV. For description, see Fig 4.
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(n=4). 100 U of TNF-α was added to the leukocytes just after
VSV adsorption and the kinetics of virus replication was studied. 
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The results indicated that the elimination of endoge-
nous IFN-α caused the largest changes in cytokine pro-
files. The changes involving TNF-α production were
suspected to be responsible for the unexpected inhibi-
tion of virus replication by the antibodies. To prove the
hypothesis, we tried to reduce the antiviral effect of the
anti-IFN-α antibodies with addition anti-TNF-α. The
results of the experiments were, however, unclear, sug-
gesting that not only TNF, but other unknown media-
tors might participate in the antiviral effect.
DISCUSSION
In view of cytokines’ antiviral activity, the question
arises whether PMBCs (resistant or sensitive to VSV)
expressing high, non-specific, antiviral resistance/innate
immunity are able to produce more cytokines than those
expressing low innate immunity. In this context we stud-
ied the production of IFN, TNF, IL-6, and IL-10. The
results of this study show differences in cytokine pro-
duction by cells with different degree of resistan-
ce/innate immunity. VSV-resistant PMBCs with good
innate immunity released more spontaneous cytokines
than PMBCs with immune deficiency. Statistical signifi-
cance, however, was found only in the case of VSV-
-induced IFN. This means that even though the cells
were not able to replicate VSV to a high level, they were
able to produce more IFN after contact with VSV than
the sensitive cells with high titers of VSV. 
The results of a previous study on the influence of
specific anti-cytokine antibodies on viral replication in
human leukocytes revealed the importance of endoge-
nous IFNs and TNF-α in maintaining antiviral innate
immunity [16]. Specific antibodies against IFN-α, IFN-
-β, IFN-γ, and TNF-α caused reductions in innate
immunity, mimicking the phenomenon observed after
stimulation of viral replication in PMBCs previously
resistant to VSV. Quite different results were obtained
when antibodies, especially antibodies against IFN-α,
were added to cells with very low innate immunity.
Instead of VSV stimulation, reduction of VSV replica-
tion was observed. We tried to find the reason for these
unexpected results. As first, a possible disturbance in
cytokine production and replacement of antiviral func-
tion of IFN by other cytokines was considered. In fact,
neutralization of IFN-α with specific antibodies caused
a disturbance in leukocyte cytokine profiles. In the
absence of endogenous IFN-α production, IL-6 was
completely abolished. The other consequence of IFN-α
elimination was stimulation of TNF-α. This higher
TNF-α production by infected leukocytes sensitive to
viral infection was assumed to be probably the reason
for this paradoxical inhibition of VSV replication.
Within the group deficient in innate immunity, TNF-α
may show an inhibitory effect on viral replication.
Antiviral activity of TNF-α has been reported by dif-
ferent authors [11, 13, 26]. For example, Mestan et al.
[13] showed that recombinant TNF-α added to the Hep-2
cell line protects the cells against VSV infection. This
effect was specific for TNF because the antiviral activity
was abolished by anti-TNF, but not by anti-IFN-α anti-
bodies This observation is in agreement with our results
obtained in VSV-sensitive PBLs. In our previous study,
however, TNF-α’s effect on VSV replication was depen-
dent on the innate immunity of the PMBCs [16]. In sen-
sitive cells, an inhibitory effect on viral replication was
observed, while in resistant PMBCs a stimulation of
VSV replication. In embryonal tissues sensitive to VSV,
inhibition of viral replication was also observed [17].
Inhibition of viral replication by TNF in sensitive leuko-
cytes was shown in this study. In cultures resistant to
infection, the opposite effect and stimulation of replica-
tion occurred [18]. Similarly, effects depending on the
level of innate immunity were noticed following culture
treatments with immunomodulating substances, i.e.
lipopolysaccharide and peptides from ovine colostrums
[5, 9]. The virus stimulatory effect, however, was elimi-
nated by antibodies against TNF-α. Our previous and
the present study indicate a double role of endogenous
TNF-α: it is responsible for both inhibition and stimula-
tion of viral replication by immunomodulators. The lack
of IL-6 production in the absence of IFN-α indicates the
necessity for this type of IFN for IL-6 production by
leukocytes. Over the years, IL-6 has been assigned both
pro- and anti-inflammatory properties. According to
Jones [10], an important role of IL-6 is directing the
transition from innate to acquired immunity; IFN-α,
through its effect on IL-6 production, could thus indi-
rectly influence this transition.
Acknowledgment: We are grateful to Prof. Maria Janusz for
critical discussions during the preparation of this manuscript.
This work was supported by the State Committee for Scientific
Research (KBN, Poland), grant no. 6P05 AA 038 20, and the
Foundation for Polish Science, grant IMMUNO no. 9.
REFERENCES
1. Baccala R., Kono D. H. and Theofilopoulos A. N. (2005):
Interferons as pathogenic effectors in autoimmunity.
Immunol. Rev., 204, 9–26.
2. B³ach-Olszewska Z. (2005): Innate immunity: cells, recep-
tors and signaling pathway. Arch. Immunol. Ther. Exp., 53,
245–253. 
3. B³ach-Olszewska Z. (2006): Mechanizmy kontroli odpor-
noœci wrodzonej [Control of over-activated innate immuni-
ty]. Postêpy Hig. Med. Doœw., 60, 201–208.
4. B³ach-Olszewska Z., Zaczyñska E., Kie³biñski M. and
Frydecka I. (2005): Deficiency of innate immunity of
leukocytes is associated with the failure of the induction of
remission and survival time in patients with acute
leukemia. Pol. J. Environmental Studies, 14 (suppl. II),
36–40.
5. Domaraczenko B., Janusz M., Orzechowska B., Jarosz W.
and B³ach-Olszewska Z. (1999): Effect of proline rich
polypeptide from ovine colostrum on virus replication in
human placenta and amniotic membrane at term; possible
B. Orzechowska et al.: Cytokines and natural immunity 116role of endogenous tumor necrosis factor. Placenta, 20,
695–701.
6. Ferlazzo G. and Munz C. (2004): NK cell compartments
and their activation by dendritic cells. J. Immunol., 172,
133.3–1339.
7. Flick D. A. and Gifford G. E. (1984): Comparison of in
vitro cell cytotoxic assays for tumor necrosis factor. J.
Immunol. Methods, 68, 167–171.
8. Fujita T., Matsushita M. and Endo Y. (2004): The lectin-
complement pathway – its role in innate immunity and evo-
lution. Immunol. Rev., 198, 185–202.
9. Jatczak B., Gejdel E., Paj¹k J., Podwiñska J. and B³ach-
Olszewska Z. (2001): Study on risk factors for transplacen-
tal viral infections; effect of bacterial factors and double
viral infections on virus replication in placenta and amni-
otic membranes. Placenta, 22, 360–371.
10. Jones S. A. (2005): Directing transition from innate to
acquired immunity: defining a role for IL-6. J. Immunol.,
175, 3463–3468.
11. Lane B. R., Markovitz D. M., Woodford N. L., Rochford
R., Strieter R. M. and Coffey M. J. (1999): TNF-alpha
inhibits HIV-1 replication in peripheral blood monocytes
and alveolar macrophages by inducing the production of
RANTES and decreasing C-C chemokine receptor 5
(CCR5) expression. J. Immunol., 163, 3653–3661.
12. Lehnardt S., Massillon L., Follett P., Jensen F. E., Ratan
R., Rosenberg P. A., Volpe J. J. and Vartanian T. (2003):
Activation of innate immunity in the CNS triggers neu-
rodegeneration through a Toll-like receptor 4-dependent
pathway. Proc. Natl. Acad. Sci. USA, 100, 8514–8519
13. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D.,
Moller A., Jacobsen H. and Kirchner H. (1986): Antiviral
effect of recombinant tumour necrosis factor in vitro.
Nature, 323, 816–819.
14. Miedzhitow R. and Biron C. A. (2003): Innate immunity.
Curr. Opin. Immunol., 15, 2–4.
15. Murray P. J. (2005): The primary mechanism of the IL-10-
-regulated antiinflammatory response is to selectively inhib-
it transcription. Proc. Natl. Acad. Sci. USA, 102, 8686–8691.
16. Orzechowska B., Antoszków Z., Siemieniec I. and B³ach-
-Olszewska Z. (2003): Individual differentiation of innate
antiviral immunity in humans; the role of endogenous
interferons and tumour necrosis factor in the immunity of
leukocytes Arch. Immunol. Ther. Exp., 51, 51–60.
17. Paradowska E., B³ach-Olszewska Z., Gierliñska M. and
Woytoñ J. (1996): Effect of exogenous tumor necrosis fac-
tor, interleukin 6, and interferons on vesicular stomatitis
virus replication in human placenta and amniotic membrane
organ cultures. Arch. Immunol. Ther. Exp., 44, 57–62.
18. Paradowska E., B³ach-Olszewska Z., Sender J. and Jarosz
W. (1996): Antiviral nonspecific immunity. Possible role of
endogenous tumor necrosis factor and interferons. J.
Interferon Cytokines Res., 16, 941–947.
19. Poea-Guyon S., Christadoss P., Le Panse R., Guyon T., De
Baets M., Wakkach A., Bidault J., Tzartos S. and Berrih-
-Aknin S. (2005): Effects of cytokines on acetylcholine
receptor expression: implications for myasthenia gravis. J.
Immunol., 174, 5941–5949.
20. Rifkin I. R., Leadbetter E. A., Busconi L., Viglianti G. and
Marshak-Rothstein A. (2005): Toll-like receptors, endoge-
nous ligands, and systemic autoimmune disease. Immunol.
Rev., 204, 27–42.
21. Rybka K., Orzechowska B., Siemieniec I., Leszek J.,
Zaczyñska E., Paj¹k J. and B³ach-Olszewska Z. (2003):
Age related natural antiviral non-specific immunity of
human leukocytes. Med. Sci. Monit., 9, BR413–417.
22. Selander B., Martensson U., Weintraub A., Holmstrom E.,
Matsushita M., Thiel S., Jensenius J. C., Truedsson L. and
Sjoholm A. G. (2006): Mannan-binding lectin activates C3
and the alternative complement pathway without involve-
ment of C2. J. Clin. Invest., 116, 1425–1434.
23. Tanga F. Y., Nutile-McMenemy N. and DeLeo J. A.
(2005): The CNS role of Toll-like receptor 4 in innate neu-
roimmunity and painful neuropathy. Proc. Natl. Acad. Sci.
USA, 102, 5856–5861.
24. Townsend K. P., Town T., Mori T., Lue L. F., Shytle D.,
Sanberg P.R., Morgan D., Fernandez F., Flavell R. A. and
Tan J. (2005): CD40 signaling regulates innate and adap-
tive activation of microglia in response to amyloid β-pep-
tide. Eur. J. Immunol., 35, 901–910.
25. Van Snick J., Cayphas S., Vink A., Uyttenhove C., Coulie
P. G., Rubira M. R. and Simpson R. J. (1986): Purifica-
tion and NH2-terminal amino acid sequence of a T-
-cell-derived lymphokine with growth factor activity for 
B-cell hybridomas. Proc. Natl. Acad. Sci. USA, 83,
9679–9683.
26. Wong G. H., Kamb A. and Goeddel D. V. (1992): Antiviral
properties of TNF. In Buetler B (ed.): Tumor necrosis fac-
tor: the molecules and their emerging role in medicine.
Raven Press Ltd., New York, pp. 371–382. 
27. Yuste J., Ali S., Sriskadan S., Hyams C., Botto M. and
Brown J. S. (2006): Roles of the alternative complement
pathway and C1q during innate immunity to Streptococcus
pyogenes. J. Immunol., 176, 6112–6120.
28. Zaczyñska E. and B³ach-Olszewska Z. (2001): Effect of
cyclosporine A on the non-specific innate immunity of
mice. Arch. Immunol Ther Exp., 49 (suppl.), S53–S57.
29. Zaczyñska E., B³ach-Olszewska Z. and Gejdel E. (1995):
Production of cytokines with antiviral activity by endothe-
lial cells. J. Interferon Cytokine Res., 15, 811–814.
B. Orzechowska et al.: Cytokines and natural immunity 117